Last $1.29 USD
Change Today 0.00 / 0.00%
Volume 237.2K
CRIS On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/21/14 - $3.40
52 Week Low
12/18/14 - $1.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

33 Employees
Last Reported Date: 03/13/14
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $464.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $142.8K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2013.

curis inc (CRIS) Key Developments

Curis, Inc.(NasdaqGM:CRIS) dropped from NASDAQ Biotechnology Index

Curis, Inc. will be removed from the NASDAQ Biotechnology Index.

Curis, Inc. Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/ Relapsed Solid Tumors

Curis, Inc. announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive (HR+)/HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in the first-in-human Phase 1 clinical study in patients with relapsed or refractory lymphomas and multiple myeloma. The solid tumor study is an open label, multi-center study to assess the safety, tolerability and pharmacokinetics of CUDC-907 in subjects with advanced, relapsed solid tumors, including hormone receptor positive breast cancer or midline carcinoma with NUT rearrangement. In the case of breast cancer, tumors must be estrogen receptor (ER+) and/or progesterone receptor (PR+) positive and HER2-negative, with disease progression following treatment with at least one prior hormonal therapy for advanced/metastatic disease or disease relapse while on adjuvant hormonal therapy. Additionally, ongoing treatment with tamoxifen, anastrozole, exemestane or letrozole is allowed. The primary objective of this study is to determine the safety and tolerability of oral CUDC-907 using the recommended schedules of administration that have already been identified in the first-in-human trial of CUDC-907, namely 5 days ‘on’/2 days ‘off’ weekly or three times a week in 21 day cycles. The secondary objectives of this study are to assess the plasma and tissue pharmacokinetics, to establish the maximum tolerated dose, the recommended Phase 2 dose in patients with solid tumor malignancies, to evaluate biomarkers of activity and the preliminary anti-cancer activity of CUDC-907. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. Specifically, CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. CUDC-907 is currently undergoing investigation in a first-in-human trial to assess its safety, pharmacokinetics and preliminary anti-cancer activity in patients with relapsed/refractory lymphomas and multiple myeloma. The development of CUDC-907 is in part supported by The Leukemia & Lymphoma Society (LLS) under a funding agreement established in 2011 between Curis and LLS's Therapy Acceleration Program.

Curis, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:00 PM

Curis, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Ali Fattaey, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $1.29 USD 0.00

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.13 USD -0.02
Delcath Systems Inc $1.35 USD -0.01
Exelixis Inc $1.33 USD +0.04
MELA Sciences Inc $1.29 USD +0.04
Navidea Biopharmaceuticals Inc $1.79 USD -0.21
View Industry Companies

Industry Analysis


Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.8x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at